Author Affiliations: Department of Emergency Medicine, New York University School of Medicine, New York (Dr Nelson) (email@example.com); and Department of Emergency Medicine, University of Pennsylvania, Philadelphia (Dr Perrone).
In Reply: We concur that the ACCME has made great strides in reducing commercial bias in medical education. The concern that we raised for independence is related to the unique CME mechanism proposed in the REMS for extended-release and long-acting (ER/LA) opioid analgesics.
Although the Blueprint for Prescriber Continuing Education Program defines the expected content of a CME program,1 it uses language that is open to interpretation. For example it states “prescribers should understand how to assess patients for treatment with ER/LA opioids” and “prescribers should be familiar with how to initiate therapy, modify dose, and discontinue use of ER/LA opioids.”
Nelson LS, Perrone J. Continuing Education in Opioid Prescribing—Reply. JAMA. 2012;308(20):2082-2083. doi:10.1001/jama.2012.13753